The Journal of Allergy and Clinical Immunology (journal-of-allergy-and-clinical-immunology)
Journal positioning
The Journal of Allergy and Clinical Immunology (JACI) is the flagship journal of the American Academy of Allergy, Asthma & Immunology (AAAAI), publishing clinical and mechanistic/translational research across allergy, asthma, and clinical immunology — atopic and respiratory allergic disease, food and drug allergy, urticaria, eosinophilic disorders, immunodeficiency, and the type 2 and broader immune mechanisms underlying these conditions. It serves allergists/immunologists and translational immunology scientists, and expects work that either changes allergy/asthma practice or delivers a clear, human-relevant immunologic mechanism; purely descriptive case series and bench studies with no allergic-disease anchor are a weak fit. This skill is a fit / venue-selection / re-framing aid; it is not clinical or regulatory advice and does not replace the journal's current instructions for authors. Before submitting, re-check the live JACI author instructions.
When to trigger
- The author names JACI for an allergy, asthma, or clinical-immunology study and wants a fit/framing check.
- A study must be re-framed around an allergic-disease mechanism or a practice-relevant allergy/asthma question with human relevance.
- The author is choosing between JACI, a general-medicine or respiratory journal, and a basic-immunology venue.
- The author needs the journal's reporting-guideline, registration, and desk-reject expectations for allergy/immunology research.
Scope & topic fit
- Asthma and allergic airway disease: phenotyping/endotyping, biologics, and type 2 inflammation mechanisms and trials.
- Food, drug, and venom allergy: diagnosis, oral immunotherapy and desensitization, and tolerance mechanisms.
- Atopic dermatitis, chronic urticaria, and other allergic skin disease — clinical and immunologic studies.
- Eosinophilic disorders, mast-cell disease, and rhinitis/rhinosinusitis with mechanistic or therapeutic advance.
- Primary and secondary immunodeficiency and immune dysregulation with clinical-immunology relevance.
- Translational immunology of allergic/immune disease (cytokine biology, barrier function, omics, immune cell profiling) anchored to human disease.
Method & evidence bar
- Clinical studies must be adequately powered with prespecified, patient-centered endpoints; biomarker/endotype endpoints need validation and justification.
- The applicable reporting guideline must be followed and its checklist supplied: CONSORT for trials, STROBE for observational studies, PRISMA for systematic reviews, STARD for diagnostic studies.
- Interventional and immunotherapy trials require prospective registration; the registration number and protocol/statistical-analysis plan are expected.
- Mechanistic/translational claims need rigorous controls, adequate replication, and validation in human samples or disease-relevant models, with appropriate immune-assay rigor (gating, isotype controls, quantification).
- Diagnostic and biomarker claims (e.g., allergy tests, endotype markers) require an independent validation cohort and an accepted reference standard.
- Observational and cohort analyses must address confounding, atopic comorbidity, and missing data; causal language must match the design.
Structure & house style
- AAAAI/Elsevier format with a structured abstract and a concise clinical-implication/capsule summary where required; re-check current article types and limits on the live guide.
- The introduction frames a focused allergy/immunology question and its mechanistic or clinical importance; the discussion states the practice or mechanistic implication plainly.
- Figures must include the controls, replication, and quantification supporting each immunologic claim; CONSORT/STROBE/PRISMA flow diagrams are expected where applicable.
- Supplements carry the protocol, full immunologic methods and reagent details, and additional cohorts/analyses.
Official-submission checklist
- Before giving submission-ready advice, read
../../resources/source-basis.md and ../../resources/official-source-map.md; start from the ICMJE/EQUATOR and AAAAI anchors, then cite the current JACI page you checked.
- Search the live site for "Journal of Allergy and Clinical Immunology guide for authors" and follow the current AAAAI/Elsevier version.
- Re-check article types, word/figure limits, structured-abstract and capsule-summary format, and statistical/immune-assay reporting requirements.
- Confirm trial registration, the reporting checklist (CONSORT/STROBE/PRISMA/STARD), data-sharing statement, and protocol/SAP submission.
- Re-check IRB/ethics and consent, animal-use approval where relevant, ICMJE authorship and conflict-of-interest disclosure, funding, and AI-use disclosure.
- If the live official instructions conflict with this skill, the official instructions win.
Pre-submission self-check
Common desk-reject triggers
- Descriptive case series or cohort slices with no mechanistic or practice advance.
- Mechanistic claims from a single model or cell line with no human validation and weak immune-assay controls.
- Biomarker/diagnostic studies without an independent validation cohort or reference standard.
- Missing trial/immunotherapy registration, protocol, or the required reporting checklist.
- Observational analyses with inadequate confounding/comorbidity handling or overstated causal claims.
- Basic immunology with no allergic-disease anchor, better served by a dedicated immunology venue.
Re-routing decision
- Respiratory-medicine emphasis where asthma/airway outcome dominates over allergy mechanism →
the-lancet-respiratory-medicine.
- Rheumatology/autoimmune musculoskeletal focus →
arthritis-and-rheumatology.
- Practice-changing, broadly significant trial → general medicine (
jama / NEJM / The Lancet in the natural-science bundle).
- Pure basic immunology with no allergic-disease translation → a basic-science immunology venue in the natural-science bundle.
- Dermatology-dominant atopic disease with no immune mechanism → a specialty dermatology venue.
Output format
[Fit] High / Medium / Low (one-line reason)
[Target] The Journal of Allergy and Clinical Immunology (AAAAI)
[Allergy/immunology tags] <2–3 closest topics, e.g. asthma biologic, food OIT, type 2 inflammation>
[Study design / reporting guideline] <RCT-CONSORT / cohort-STROBE / review-PRISMA / diagnostic-STARD / mechanistic>
[Method/evidence] <power, endpoint/biomarker validity, human validation, registration>
[Top risk] <the single most likely reason for rejection>
[Official items to re-check] <article type / registration / checklist / ethics / disclosures>
[Re-route suggestion] <if not a fit, a better-matched venue>
Source: brycewang-stanford/Awesome-Journal-Skills → Clinical-Medicine-Journal-Skills/skills/journal-of-allergy-and-clinical-immunology/SKILL.md
1---2name: journal-of-allergy-and-clinical-immunology3description: Use when targeting The Journal of Allergy and Clinical Immunology (JACI) or deciding whether an allergy/asthma/clinical-immunology study fits this venue. Encodes the journal's fit, the clinical-and-mechanistic immunology evidence bar, reporting-guideline and registration requirements, AAAAI/Elsevier house style, official-submission re-check, and desk-reject heuristics. Venue-fit aid only, not clinical advice.4---5
6
7# The Journal of Allergy and Clinical Immunology (journal-of-allergy-and-clinical-immunology)
8
9## Journal positioning
10
11The Journal of Allergy and Clinical Immunology (JACI) is the flagship journal of the American Academy of Allergy, Asthma & Immunology (AAAAI), publishing clinical and mechanistic/translational research across allergy, asthma, and clinical immunology — atopic and respiratory allergic disease, food and drug allergy, urticaria, eosinophilic disorders, immunodeficiency, and the type 2 and broader immune mechanisms underlying these conditions. It serves allergists/immunologists and translational immunology scientists, and expects work that either changes allergy/asthma practice or delivers a clear, human-relevant immunologic mechanism; purely descriptive case series and bench studies with no allergic-disease anchor are a weak fit. This skill is a **fit / venue-selection / re-framing** aid; it is not clinical or regulatory advice and does not replace the journal's current instructions for authors. Before submitting, re-check the live JACI author instructions.
12
13## When to trigger
14
15- The author names JACI for an allergy, asthma, or clinical-immunology study and wants a fit/framing check.
16- A study must be re-framed around an allergic-disease mechanism or a practice-relevant allergy/asthma question with human relevance.
17- The author is choosing between JACI, a general-medicine or respiratory journal, and a basic-immunology venue.
18- The author needs the journal's reporting-guideline, registration, and desk-reject expectations for allergy/immunology research.
19
20## Scope & topic fit
21
22- Asthma and allergic airway disease: phenotyping/endotyping, biologics, and type 2 inflammation mechanisms and trials.
23- Food, drug, and venom allergy: diagnosis, oral immunotherapy and desensitization, and tolerance mechanisms.
24- Atopic dermatitis, chronic urticaria, and other allergic skin disease — clinical and immunologic studies.
25- Eosinophilic disorders, mast-cell disease, and rhinitis/rhinosinusitis with mechanistic or therapeutic advance.
26- Primary and secondary immunodeficiency and immune dysregulation with clinical-immunology relevance.
27- Translational immunology of allergic/immune disease (cytokine biology, barrier function, omics, immune cell profiling) anchored to human disease.
28
29## Method & evidence bar
30
31- Clinical studies must be adequately powered with prespecified, patient-centered endpoints; biomarker/endotype endpoints need validation and justification.
32- The applicable reporting guideline must be followed and its checklist supplied: CONSORT for trials, STROBE for observational studies, PRISMA for systematic reviews, STARD for diagnostic studies.
33- Interventional and immunotherapy trials require prospective registration; the registration number and protocol/statistical-analysis plan are expected.
34- Mechanistic/translational claims need rigorous controls, adequate replication, and validation in human samples or disease-relevant models, with appropriate immune-assay rigor (gating, isotype controls, quantification).
35- Diagnostic and biomarker claims (e.g., allergy tests, endotype markers) require an independent validation cohort and an accepted reference standard.
36- Observational and cohort analyses must address confounding, atopic comorbidity, and missing data; causal language must match the design.
37
38## Structure & house style
39
40- AAAAI/Elsevier format with a structured abstract and a concise clinical-implication/capsule summary where required; re-check current article types and limits on the live guide.
41- The introduction frames a focused allergy/immunology question and its mechanistic or clinical importance; the discussion states the practice or mechanistic implication plainly.
42- Figures must include the controls, replication, and quantification supporting each immunologic claim; CONSORT/STROBE/PRISMA flow diagrams are expected where applicable.
43- Supplements carry the protocol, full immunologic methods and reagent details, and additional cohorts/analyses.
44
45## Official-submission checklist
46
47- Before giving submission-ready advice, read `../../resources/source-basis.md` and `../../resources/official-source-map.md`; start from the ICMJE/EQUATOR and AAAAI anchors, then cite the current JACI page you checked.
48- Search the live site for "Journal of Allergy and Clinical Immunology guide for authors" and follow the current AAAAI/Elsevier version.
49- Re-check article types, word/figure limits, structured-abstract and capsule-summary format, and statistical/immune-assay reporting requirements.
50- Confirm trial registration, the reporting checklist (CONSORT/STROBE/PRISMA/STARD), data-sharing statement, and protocol/SAP submission.
51- Re-check IRB/ethics and consent, animal-use approval where relevant, ICMJE authorship and conflict-of-interest disclosure, funding, and AI-use disclosure.
52- If the live official instructions conflict with this skill, the official instructions win.
53
54## Pre-submission self-check
55
56- [ ] The study answers a focused allergy/immunology question with a clear mechanistic or practice implication and human relevance.
57- [ ] Clinical endpoints are prespecified and patient-centered; biomarker/endotype endpoints are validated.
58- [ ] Mechanistic claims rest on adequately controlled, replicated immune assays, ideally validated in human samples.
59- [ ] The correct reporting checklist (CONSORT/STROBE/PRISMA/STARD) is completed and attached.
60- [ ] Immunotherapy/interventional trials are prospectively registered with the number in the manuscript; protocol/SAP provided.
61- [ ] IRB/consent, ICMJE disclosures, and a data-sharing statement are prepared.
62
63## Common desk-reject triggers
64
65- Descriptive case series or cohort slices with no mechanistic or practice advance.
66- Mechanistic claims from a single model or cell line with no human validation and weak immune-assay controls.
67- Biomarker/diagnostic studies without an independent validation cohort or reference standard.
68- Missing trial/immunotherapy registration, protocol, or the required reporting checklist.
69- Observational analyses with inadequate confounding/comorbidity handling or overstated causal claims.
70- Basic immunology with no allergic-disease anchor, better served by a dedicated immunology venue.
71
72## Re-routing decision
73
74- Respiratory-medicine emphasis where asthma/airway outcome dominates over allergy mechanism → `the-lancet-respiratory-medicine`.
75- Rheumatology/autoimmune musculoskeletal focus → `arthritis-and-rheumatology`.
76- Practice-changing, broadly significant trial → general medicine (`jama` / NEJM / The Lancet in the natural-science bundle).
77- Pure basic immunology with no allergic-disease translation → a basic-science immunology venue in the natural-science bundle.
78- Dermatology-dominant atopic disease with no immune mechanism → a specialty dermatology venue.
79
80## Output format
81
82```text
83[Fit] High / Medium / Low (one-line reason)
84[Target] The Journal of Allergy and Clinical Immunology (AAAAI)
85[Allergy/immunology tags] <2–3 closest topics, e.g. asthma biologic, food OIT, type 2 inflammation>
86[Study design / reporting guideline] <RCT-CONSORT / cohort-STROBE / review-PRISMA / diagnostic-STARD / mechanistic>
87[Method/evidence] <power, endpoint/biomarker validity, human validation, registration>
88[Top risk] <the single most likely reason for rejection>
89[Official items to re-check] <article type / registration / checklist / ethics / disclosures>
90[Re-route suggestion] <if not a fit, a better-matched venue>
91```
92
93---
94
95**Source:** [`brycewang-stanford/Awesome-Journal-Skills`](https://github.com/brycewang-stanford/Awesome-Journal-Skills) → `Clinical-Medicine-Journal-Skills/skills/journal-of-allergy-and-clinical-immunology/SKILL.md`
thedixitjain